Valuation
- Market cap
- 284,473,000
- Revenue TTM
- $0
- Net income TTM
- $-1,445,603
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 94,300
- Avg volume
- 118,248
- Day's range
- $16.18 – $19.25
- Shares out
- 14,855,000
- Stochastic %K
- 8%
- Beta
- —
- Analysts
- Moderate Buy
- Price target
- $48.50
Company profile
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United Sta...
Show more
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 919 659 5677
- Website
- https://vogenx.com
- Address
- 3901 Barrett Drive, Suite 300, Raleigh, United States
Latest news
No headlines yet.
